AstraZeneca, Daiichi Sankyo's Enhertu gets FDA approval for lung cancer subtype

Aug. 12, 2022 7:17 AM ETAstraZeneca PLC (AZN), DSKYF, DSNKYBy: Ravikash, SA News Editor

AstraZeneca production plant

Roland Magnusson/iStock Editorial via Getty Images

  • The U.S. Food and Drug Administration (FDA) approved AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo's (OTCPK:DSKYF) (OTCPK:DSNKY) Enhertu to treat adult patients with unresectable or metastatic non-small cell lung

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.